Diagnosis and Management of Type II Myocardial Infarction: Increased Demand for a Limited Supply of Evidence

Current Atherosclerosis Reports

Volumn 17, Issue 2, 2015, Pages

  Smilowitz, Nathaniel R ^a   Naoulou, Becky ^a   Sedlis, Steven P ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

Author keywords

Anemia; Bradyarrhythmia; Endothelial dysfunction; Hypertension; Hypotension; Hypoxia; Myocardial infarction; Myocardial necrosis; Perioperative MI; Respiratory failure; Sepsis; Shock; Supply demand mismatch; Tachyarrhythmia; Type 2; Vasospasm

Indexed keywords

C REACTIVE PROTEIN; TROPONIN; BIOLOGICAL MARKER; TROPONIN I;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY ARTERY SPASM; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE NECROSIS; HEART MUSCLE OXYGEN CONSUMPTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; LEUKOCYTE COUNT; MORTALITY; PATHOPHYSIOLOGY; PREVALENCE; PROGNOSIS; REVIEW; TYPE 2 MYOCARDIAL INFARCTION; BLOOD; CLASSIFICATION; ELECTROCARDIOGRAPHY; MYOCARDIAL INFARCTION;

BIOLOGICAL MARKERS; CORONARY ANGIOGRAPHY; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; PROGNOSIS; TROPONIN I;

EID: 84922442263     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0478-1     Document Type: Review

References (45)

1. Thygesen K, Mair J, Katus H, Plebani M, Venge P, Collinson P, et al. Recommendations for the use of cardiac troponin measurement in acute cardiac care. Eur Heart J. 2010;31:2197–204.
2. Landesberg G, Vesselov Y, Einav S, Goodman S, Sprung CL, Weissman C. Myocardial ischemia, cardiac troponin, and long-term survival of high-cardiac risk critically ill intensive care unit patients. Crit Care Med. 2005;33:1281–7.
3. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD, et al. Third universal definition of myocardial infarction. J Am Coll Cardiol. 2012;60:1581–98. This preference provides the accepted modern definition of myocardial infarction and defines the 5 major subtypes.
4. Ammann P, Fehr T, Minder EI, Gunter C, Bertel O. Elevation of troponin i in sepsis and septic shock. Intensive Care Med. 2001;27:965–9.
5. Mehta NJ, Khan IA, Gupta V, Jani K, Gowda RM, Smith PR. Cardiac troponin i predicts myocardial dysfunction and adverse outcome in septic shock. Int J Cardiol. 2004;95:13–7.
6. ver Elst KM, Spapen HD, Nguyen DN, Garbar C, Huyghens LP, Gorus FK. Cardiac troponins i and t are biological markers of left ventricular dysfunction in septic shock. Clin Chem. 2000;46:650–7.
7. Arlati S, Brenna S, Prencipe L, Marocchi A, Casella GP, Lanzani M, et al. Myocardial necrosis in ICU patients with acute non-cardiac disease: a prospective study. Intensive Care Med. 2000;26:31–7.
8. Vasile VC, Babuin L, Rio Perez JA, Alegria JR, Song LM, Chai HS, et al. Long-term prognostic significance of elevated cardiac troponin levels in critically ill patients with acute gastrointestinal bleeding. Crit Care Med. 2009;37:140–7.
9. Iser DM, Thompson AJ, Sia KK, Yeomans ND, Chen RY. Prospective study of cardiac troponin i release in patients with upper gastrointestinal bleeding. J Gastroenterol Hepatol. 2008;23:938–42.
10. Zellweger MJ, Schaer BA, Cron TA, Pfisterer ME, Osswald S. Elevated troponin levels in absence of coronary artery disease after supraventricular tachycardia. Swiss Med Wkly. 2003;133:439–41.
11. Bukkapatnam RN, Robinson M, Turnipseed S, Tancredi D, Amsterdam E, Srivatsa UN. Relationship of myocardial ischemia and injury to coronary artery disease in patients with supraventricular tachycardia. Am J Cardiol. 2010;106:374–7.
12. Chow GV, Hirsch GA, Spragg DD, Cai JX, Cheng A, Ziegelstein RC, et al. Prognostic significance of cardiac troponin i levels in hospitalized patients presenting with supraventricular tachycardia. Medicine. 2010;89:141–8.
13. Pattanshetty DJ, Bhat PK, Aneja A, Pillai DP. Elevated troponin predicts long-term adverse cardiovascular outcomes in hypertensive crisis: a retrospective study. J Hypertens. 2012;30:2410–5.
14. Stein GY, Herscovici G, Korenfeld R, Matetzky S, Gottlieb S, Alon D, et al. Type-ii myocardial infarction–patient characteristics, management and outcomes. PLoS One. 2014;9:e84285.
15. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Pyndt Diederichsen AC, Hallas J, et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med. 2013;126:789–97. This reference outlines general clinical characteristics of patients who develop Type 2 myocardial infarction and provides a set of definitions for conditions predisposing to mismatch in myocardial oxygen supply and demand.
16. McFalls EO, Larsen G, Johnson GR, Apple FS, Goldman S, Arai A, et al. Outcomes of hospitalized patients with non-acute coronary syndrome and elevated cardiac troponin level. Am J Med. 2011;124:630–5. This is the largest study to evaluate long-term outcomes in patients with positive troponins associated with non-acute coronary syndrome conditions.
17. Saaby L, Poulsen TS, Diederichsen AC, Hosbond S, Larsen TB, Schmidt H, et al. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. Am J Med. 2014;127:295–302.
18. Javed U, Aftab W, Ambrose JA, Wessel RJ, Mouanoutoua M, Huang G, et al. Frequency of elevated troponin i and diagnosis of acute myocardial infarction. Am J Cardiol. 2009;104:9–13.
19. Lim W, Qushmaq I, Devereaux PJ, Heels-Ansdell D, Lauzier F, Ismaila AS, et al. Elevated cardiac troponin measurements in critically ill patients. Arch Intern Med. 2006;166:2446–54.
20. Wu TT, Yuan A, Chen CY, Chen WJ, Luh KT, Kuo SH, et al. Cardiac troponin i levels are a risk factor for mortality and multiple organ failure in noncardiac critically ill patients and have an additive effect to the apache ii score in outcome prediction. Shock. 2004;22:95–101.
21. Quenot JP, Le Teuff G, Quantin C, Doise JM, Abrahamowicz M, Masson D, et al. Myocardial injury in critically ill patients: relation to increased cardiac troponin i and hospital mortality. Chest. 2005;128:2758–64.
22. Babuin L, Vasile VC, Rio Perez JA, Alegria JR, Chai HS, Afessa B, et al. Elevated cardiac troponin is an independent risk factor for short- and long-term mortality in medical intensive care unit patients. Crit Care Med. 2008;36:759–65.
23. Wright RS, Williams BA, Cramner H, Gallahue F, Willmore T, Lewis L, et al. Elevations of cardiac troponin i are associated with increased short-term mortality in noncardiac critically ill emergency department patients. Am J Cardiol. 2002;90:634–6.
24. Vasile VC, Chai HS, Abdeldayem D, Afessa B, Jaffe AS. Elevated cardiac troponin t levels in critically ill patients with sepsis. Am J Med. 2013;126:1114–21.
25. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative myocardial infarction. Circulation. 2009;119:2936–44.
26. Oberweis BS, Nukala S, Rosenberg A, Guo Y, Stuchin S, Radford MJ, et al. Thrombotic and bleeding complications after orthopedic surgery. Am Heart J. 2013;165:427–33. e421.
27. Vascular Events In Noncardiac Surgery Patients Cohort Evaluation Study I, Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, et al. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012;307:2295–304.
28. Devereaux PJ, Xavier D, Pogue J, Guyatt G, Sigamani A, Garutti I, et al. Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. Ann Intern Med. 2011;154:523–8.
29. Melberg T, Burman R, Dickstein K. The impact of the 2007 esc-acc-aha-whf universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study. Int J Cardiol. 2010;139:228–33.
30. Morrow DA, Wiviott SD, White HD, Nicolau JC, Bramucci E, Murphy SA, et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38: an application of the classification system from the universal definition of myocardial infarction. Circulation. 2009;119:2758–64.
31. Bonaca MP, Wiviott SD, Braunwald E, Murphy SA, Ruff CT, Antman EM, et al. American College of Cardiology/American Heart Association/European Society of Cardiology/World Heart Federation universal definition of myocardial infarction classification system and the risk of cardiovascular death: observations from the triton-timi 38 trial (trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-thrombolysis in myocardial infarction 38). Circulation. 2012;125:577–83.
32. Ambrose JA, Loures-Vale A, Javed U, Buhari CF, Aftab W. Angiographic correlates in type 1 and 2 mi by the universal definition. J Am Coll Cardiol Img. 2012;5:463–4.
33. Ammann P, Maggiorini M, Bertel O, Haenseler E, Joller-Jemelka HI, Oechslin E, et al. Troponin as a risk factor for mortality in critically ill patients without acute coronary syndromes. J Am Coll Cardiol. 2003;41:2004–9.
34. Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded. Ann Intern Med. 2005;142:786–91.
35. Logeart D, Beyne P, Cusson C, Tokmakova M, Leban M, Guiti C, et al. Evidence of cardiac myolysis in severe nonischemic heart failure and the potential role of increased wall strain. Am Heart J. 2001;141:247–53.
36. Cunnion RE, Schaer GL, Parker MM, Natanson C, Parrillo JE. The coronary circulation in human septic shock. Circulation. 1986;73:637–44.
37. Altmann DR, Korte W, Maeder MT, Fehr T, Haager P, Rickli H, et al. Elevated cardiac troponin i in sepsis and septic shock: no evidence for thrombus associated myocardial necrosis. PLoS One. 2010;5:e9017.
38. Januzzi Jr JL, Filippatos G, Nieminen M, Gheorghiade M. Troponin elevation in patients with heart failure: on behalf of the third universal definition of myocardial infarction global task force: heart failure section. Eur Heart J. 2012;33:2265–71.
39. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O’Connor CM, Felker GM. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010;56:1071–8.
40. Shah RV, Chen-Tournoux AA, Picard MH, Januzzi JL. Association between troponin t and impaired left ventricular relaxation in patients with acute decompensated heart failure with preserved systolic function. Eur J Echocardiogr: J Work Group Echocardiogr Eur Soc Cardiol. 2009;10:765–8.
41. Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375–80.
42. Dispenzieri A, Kyle RA, Gertz MA, Therneau TM, Miller WL, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787–9.
43. Lauer B, Niederau C, Kuhl U, Schannwell M, Pauschinger M, Strauer BE, et al. Cardiac troponin t in patients with clinically suspected myocarditis. J Am Coll Cardiol. 1997;30:1354–9.
44. Landesberg G. Monitoring for myocardial ischemia. Best Prac Res Clin Anaesthesiol. 2005;19:77–95.
45. Alpert JS, Thygesen KA, White HD, Jaffe AS. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med. 2014;127:105–8.